1-7 of 7
Sasa Dimitrijevic
Close
Sort by
Journal Articles

Avapritinib As First-Line Therapy in Patients with Advanced Systemic Mastocytosis: Efficacy and Safety from the Pathfinder Clinical Study

Deepti H. Radia, Jason Gotlib, Mark W. Drummond, Tracy I. George, Hui-Min Lin, Saša Dimitrijević, Javier I. Munoz-Gonzalez, Ilda Bidollari, Michael W. Deininger, Daniel J. DeAngelo, Andreas Reiter
Journal: Blood
Blood (2022) 140 (Supplement 1): 1509–1511.
https://doi.org/10.1182/blood-2022-166986
Published: 2022
Journal Articles

AZURE: A Phase 1/2 Study of Blu-263 As Monotherapy and in Combination with Azacitidine in Patients with Advanced Systemic Mastocytosis

Daniel J. DeAngelo, Andreas Reiter, Tracy I. George, Deepti H. Radia, Marissa Devlin, Saša Dimitrijević, Mikael Rinne, Robyn Scherber, Jason Gotlib
Journal: Blood
Blood (2022) 140 (Supplement 1): 6877–6878.
https://doi.org/10.1182/blood-2022-167410
Published: 2022
Journal Articles

An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety

Daniel J. DeAngelo, Deepti H. Radia, Tracy I. George, William A. Robinson, Albert T. Quiery, Mark W. Drummond, Prithviraj Bose, Elizabeth O. Hexner, Elliott Winton, Hans-Peter Horny, Meera Tugnait, Hui-Min Lin, Saša Dimitrijević, Javier I. Munoz-Gonzalez, Ilda Bidollari, Michael W. Deininger, Jason Gotlib
Journal: Blood
Blood (2022) 140 (Supplement 1): 3932–3934.
https://doi.org/10.1182/blood-2022-167593
Published: 2022
Journal Articles

Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study

Tracy I. George, Kristin H. Karner, Karen A. Moser, Anton Rets, Michelle Fredericks, Andreas Reiter, Deepti H. Radia, Michael W. Deininger, Hui-Min Lin, Jayita Sen, Jason Gotlib, Saša Dimitrijević, Daniel J. DeAngelo
Journal: Blood
Blood (2021) 138 (Supplement 1): 2565.
https://doi.org/10.1182/blood-2021-146873
Published: 2021
Journal Articles

A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma

Graham P. Collins, MD PhD, Rakesh Popat, Anastasios Stathis, Fatime Krasniqi, MD PhD, Toby A. Eyre, MD, Chin Hin Ng, MD, Dima El-Sharkawi, MD, Christian Schmidt, MD, Andreas Wicki, MDPhD, Elena Ivanova, PhD, Debora Schmitz, PhD, Sasa Dimitrijevic, PhD, Martin H. Dreyling, MD PhD
Journal: Blood
Blood (2016) 128 (22): 5893.
https://doi.org/10.1182/blood.V128.22.5893.5893
Published: 2016
Journal Articles

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib

Clinical Trials & Observations
Petri Bono, Andreas Krause, Margaret von Mehren, Michael C. Heinrich, Charles D. Blanke, Sasa Dimitrijevic, George D. Demetri, Heikki Joensuu
Journal: Blood
Blood (2004) 103 (8): 2929–2935.
https://doi.org/10.1182/blood-2003-10-3443
Published: 2004
Journal Articles

The c- KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

Yongsheng Ma, Shan Zeng, Dean D. Metcalfe, Cem Akin, Sasa Dimitrijevic, Joseph H. Butterfield, Gerald McMahon, B. Jack Longley
Journal: Blood
Blood (2002) 99 (5): 1741–1744.
https://doi.org/10.1182/blood.V99.5.1741
Published: 2002